

# Nikos Pantazis

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4404947/nikos-pantazis-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68

papers

2,363

citations

25

h-index

48

g-index

75

ext. papers

2,754

ext. citations

5.2

avg. IF

4.31

L-index

#	Paper	IF	Citations
68	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination.. <i>Vaccines</i> , <b>2022</b> , 10,	5.3	3
67	Disease progression and mortality with untreated HIV infection: evidence synthesis of HIV seroconverter cohorts, antiretroviral treatment clinical cohorts and population-based survey data. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24 Suppl 5, e25784	5.4	0
66	HIV continuum of care: expanding scope beyond a cross-sectional view to include time analysis: a systematic review. <i>BMC Public Health</i> , <b>2021</b> , 21, 1699	4.1	0
65	Discriminating Between Premigration and Postmigration HIV Acquisition Using Surveillance Data. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2021</b> , 88, 117-124	3.1	0
64	Effectiveness of fissure sealants on initial caries lesions (ICDAS 1-3) of permanent molars: A 4-year follow-up. <i>European Journal of Paediatric Dentistry</i> , <b>2021</b> , 22, 180-188	1.1	
63	Misspecifying the covariance structure in a linear mixed model under MAR drop-out. <i>Statistics in Medicine</i> , <b>2020</b> , 39, 3027-3041	2.3	
62	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 2905-2916 <sup>3</sup>	11.6	3
61	What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? Perspectives from European HIV cohorts. <i>HIV Medicine</i> , <b>2020</b> , 21 Suppl 2, 3-16	2.7	7
60	Preliminary Data of a Quantitative Point of Care Test for SARS-CoV-2 Antibodies From Greece. <i>In Vivo</i> , <b>2020</b> , 34, 3039-3045	2.3	2
59	The carotico-clinoid bar: A systematic review and meta-analysis of its prevalence and potential implications in cerebrovascular and skull base surgery. <i>World Neurosurgery</i> , <b>2019</b> , 124, 267-267	2.1	3
58	Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy. <i>Aids</i> , <b>2019</b> , 33, 1645-1655	3.5	2
57	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. <i>Aids</i> , <b>2019</b> , 33, 327-337	3.5	3
56	HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors. <i>BMC Medicine</i> , <b>2019</b> , 17, 4	11.4	27
55	Longitudinal and time-to-drop-out joint models can lead to seriously biased estimates when the drop-out mechanism is at random. <i>Biometrics</i> , <b>2019</b> , 75, 58-68	1.8	5
54	Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 53, 294-301	14.3	28
53	Determining the likely place of HIV acquisition for migrants in Europe combining subject-specific information and biomarkers data. <i>Statistical Methods in Medical Research</i> , <b>2019</b> , 28, 1979-1997	2.3	8
52	Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors. <i>Annals of Gastroenterology</i> , <b>2019</b> , 32, 99-106	2.2	4

51	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 893-903	11.6	75
50	Potential adjustment methodology for missing data and reporting delay in the HIV Surveillance System, European Union/European Economic Area, 2015. <i>Eurosurveillance</i> , <b>2018</b> , 23,	19.8	4
49	Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion. <i>HIV Medicine</i> , <b>2018</b> , 19, 184-194	2.7	27
48	HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay. <i>HIV Medicine</i> , <b>2018</b> , 19, 33-41	2.7	9
47	The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort. <i>PLoS ONE</i> , <b>2018</b> , 13, e0203601	3.7	2
46	A randomized trial comparing concise and standard consent forms in the START trial. <i>PLoS ONE</i> , <b>2017</b> , 12, e0172607	3.7	22
45	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2862-2868	5.1	4
44	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 76, 311-318	3.1	8
43	Using CD4 Data to Estimate HIV Incidence, Prevalence, and Percent of Undiagnosed Infections in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 74, 3-9	3.1	69
42	Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. <i>Aids</i> , <b>2017</b> , 31, 835-846	3.5	11
41	High levels of postmigration HIV acquisition within nine European countries. <i>Aids</i> , <b>2017</b> , 31, 1979-1988	3.5	69
40	Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. <i>HIV Medicine</i> , <b>2017</b> , 18, 33-44	2.7	10
39	Birth order and memories of traumatic and family experiences in Greek patients with borderline personality disorder versus patients with other personality disorders. <i>Bulletin of the Menninger Clinic</i> , <b>2016</b> , 80, 234-54	1.3	3
38	A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation Model. <i>Epidemiology</i> , <b>2016</b> , 27, 247-56	3.1	5
37	Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005661	7.6	98
36	The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. <i>Aids</i> , <b>2016</b> , 30, 879-88	3.5	8
35	Emergency care provided in a Greek dental school and analysis of the patients' demographic characteristics: a prospective study. <i>International Dental Journal</i> , <b>2016</b> , 66, 280-6	2.2	9
34	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV</i> , <b>2015</b> , 2, e335-43	7.8	41

33	Treatment Modifications and Treatment-Limiting Toxicities or Side Effects: Risk Factors and Temporal Trends. <i>AIDS Research and Human Retroviruses</i> , <b>2015</b> , 31, 707-17	1.6	1
32	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. <i>Aids</i> , <b>2015</b> , 29, 2323-33	3.5	14
31	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. <i>Lancet HIV,the</i> , <b>2014</b> , 1, e119-26	7.8	24
30	Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. <i>Aids</i> , <b>2014</b> , 28, 1351-6	3.5	27
29	The permanent deformation of the self-adjusting files when used in canals of extracted teeth. <i>International Endodontic Journal</i> , <b>2013</b> , 46, 863-9	5.4	6
28	Performance of parametric survival models under non-random interval censoring: A simulation study. <i>Computational Statistics and Data Analysis</i> , <b>2013</b> , 63, 16-30	1.6	0
27	Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 888-97	11.6	76
26	The influence of different power settings of Nd:YAG laser irradiation, bioglass and combination to the occlusion of dentinal tubules. <i>Photomedicine and Laser Surgery</i> , <b>2013</b> , 31, 54-8		18
25	Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. <i>PLoS ONE</i> , <b>2013</b> , 8, e71174	3.7	11
24	Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. <i>PLoS ONE</i> , <b>2012</b> , 7, e32369	3.7	27
23	Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 111-8	11.6	14
22	Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals. <i>Journal of Chemotherapy</i> , <b>2012</b> , 24, 38-47	2.3	2
21	Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds . <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 817-25	11.6	155
20	Analyzing Longitudinal Data in the Presence of Informative Dropout: The Jmre1 Command. <i>The Stata Journal</i> , <b>2010</b> , 10, 226-251	3.5	7
19	The optimal home blood pressure monitoring schedule based on the Didima outcome study. <i>Journal of Human Hypertension</i> , <b>2010</b> , 24, 158-64	2.6	42
18	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , <b>2010</b> , 376, 340-5 <sup>40</sup>		77
17	CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. <i>Aids</i> , <b>2010</b> , 24, 2697-704	3.5	27
16	Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. <i>Aids</i> , <b>2009</b> , 23, 2029-37	3.5	54

15	Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. <i>American Journal of Epidemiology</i> , <b>2008</b> , 168, 532-40	3.8	71
14	The effect of antiretroviral treatment of different durations in primary HIV infection. <i>Aids</i> , <b>2008</b> , 22, 2441-50	3.5	23
13	Response to combination antiretroviral therapy: variation by age. <i>Aids</i> , <b>2008</b> , 22, 1463-73	3.5	173
12	Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2008</b> , 49, 492-8	3.1	10
11	Robustness of a parametric model for informatively censored bivariate longitudinal data under misspecification of its distributional assumptions: A simulation study. <i>Statistics in Medicine</i> , <b>2007</b> , 26, 5473-85	2.3	7
10	Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. <i>Aids</i> , <b>2007</b> , 21, 1283-91	3.5	25
9	Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2006</b> , 42, 554-61	3.1	54
8	Bivariate modelling of longitudinal measurements of two human immunodeficiency type 1 disease progression markers in the presence of informative drop-outs. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , <b>2005</b> , 54, 405-423	1.5	19
7	Frequency and distribution of root filled teeth and apical periodontitis in a Greek population. <i>International Endodontic Journal</i> , <b>2005</b> , 38, 105-11	5.4	73
6	Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. <i>Aids</i> , <b>2004</b> , 18, 2261-7	3.5	37
5	Changes in T cell receptor excision DNA circle (TREC) levels in HIV type 1-infected subjects pre- and post-highly active antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , <b>2004</b> , 20, 47-54	1.6	9
4	Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. <i>Aids</i> , <b>2004</b> , 18, 1697-705	3.5	48
3	Elevated serum levels of soluble immune activation markers are associated with increased risk for death in HAART-naive HIV-1-infected patients. <i>AIDS Patient Care and STDs</i> , <b>2003</b> , 17, 147-53	5.8	16
2	Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. <i>Journal of Virology</i> , <b>2002</b> , 76, 10099-108	6.6	75
1	Comparison of evidence of treatment effects in randomized and nonrandomized studies. <i>JAMA - Journal of the American Medical Association</i> , <b>2001</b> , 286, 821-30	27.4	567